PureTech Health PLC
PRTC
Detailliertes Diagramm anzeigen
16.500USD
-1.000-5.71%
Handelsschluss 11/10, 16:00（ET）Kurse um 15 Minuten verzögert
3.96BMarktkapitalisierung
--KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-5.71%
5 Tage
-7.04%
1 Monat
-7.20%
6 Monate
-1.67%
Seit Jahresbeginn
-10.62%
1 Jahr
-20.86%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von PureTech Health PLC
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Starker Kauf bewertet. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
PureTech Health PLC Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Starker Kauf
Aktuelles Rating
46.000
Kursziel
+162.86%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
PureTech Health PLC Highlights
HöhepunkteRisiko
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
performance_growth_period
performance_growth_period_desc%!(EXTRA string=4.83M)
performance_turn_profit
performance_turn_profit_desc%!(EXTRA string=)
valuation_reasonable
valuation_reasonable_desc%!(EXTRA string=PE, string=101.38)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=355.84K, string=14.97%)
PureTech Health PLC Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
PureTech Health PLC Informationen
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
BörsenkürzelPRTC
UnternehmenPureTech Health PLC
CEOMr. Robert (Rob) Lyne
Websitehttps://puretechhealth.com/
Verwandte Finanzinstrumente
+4.57%
+0.99%
-0.21%
+3.43%
+0.67%
+0.54%
+1.08%
+0.57%
-0.58%
-0.16%
+2.01%
+2.86%
+0.87%
+1.22%
+1.57%
+1.16%
0.00%
-0.42%
-0.23%
+1.78%Beliebte Symbole
